ReviewThe FEBS journal2025
In vivo and in silico models of Drosophila for Parkinson's disease.
Review in The FEBS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Dose-response toxicity and locomotor effects ofFrontiers in toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The fruit fly Drosophila melanogaster has emerged as an important model organism to shed light on neurodegeneration. Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder, the cause of which is still mostly unclear. The long-term use of available PD drugs may have major side effects, and they only target the symptoms without providing any effective cure for the disease. Therefore, in vivo and in silico approaches are extensively used to model PD-like phenotypes in Drosophila and investigate cellular alterations underlying PD pathogenesis. In vivo models are particularly crucial to provide insight into the PD-related molecular processes. It has been a preferred approach to investigate these models by collecting omics datasets, which can be further analysed using in silico modeling such as genome-scale metabolic models and artificial intelligence applications. This review aims to summarise in vivo and in silico modeling studies in the literature to illustrate the potential of the Drosophila in the characterisation of PD-related biological mechanisms towards providing early biomarkers and novel treatment options for PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.